KURA

MKT CAP:$817M

Kura Oncology, Inc.

Market Cap

$817M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$9.29-$1.05 (-10.20%)

Apr 24, 2026

Company Details

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product ...

CEO

Troy Edward Wilson

IPO Date

Sep 16, 2015

Website

kuraoncology.com

Key Metrics TTM

Revenue

$67M

+25.2% YoY

Net Income

-$279M

EPS (Diluted)

-$3.18

Free Cash Flow

-$71M

Revenue / Share

$0.77

Gross Margin

94.6%

Operating Margin

-449.9%

Net Margin

-412.9%

FCF Margin

-104.8%

P/S

12.1x

P/E

—

Earnings Reports

Q1 2026

May 7, 2026

PENDING

FY 2025

Mar 5, 2026

$67M+25.2%EPS -$3.18

Q4 2025

Mar 5, 2026

$17M-67.8%EPS -$0.92

Q3 2025

Nov 4, 2025

$21MEPS -$0.85

Q2 2025

Aug 7, 2025

$15MEPS -$0.75

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$33M
Q2 22	$0	$0	-$35M
Q3 22	$0	$0	-$37M
Q4 22	$0	$0	-$35M
Q1 23	$0	$0	-$37M
Q2 23	$0	$0	-$40M
Q3 23	$0	-$216.0K	-$42M
Q4 23	$0	-$214.0K	-$47M
Q1 24	$0	-$234.0K	-$54M
Q2 24	$0	-$202.0K	-$56M
Q3 24	$0	$0	-$60M
Q4 24	$54M	$54M	-$22M
Q1 25	$14M	$14M	-$65M
Q2 25	$15M	$15M	-$73M
Q3 25	$21M	$18M	-$80M
Q4 25	$17M	$17M	-$86M

Valuation

Quarter	P/S	P/E
Q1 22	—	—
Q2 22	—	—
Q3 22	—	—
Q4 22	—	—
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	—	—
Q3 24	—	—
Q4 24	13.8x	—
Q1 25	8.5x	—
Q2 25	6.1x	—
Q3 25	7.6x	—
Q4 25	13.6x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$32M	-$32M
Q2 22	-$30M	-$31M
Q3 22	-$21M	-$21M
Q4 22	-$27M	-$27M
Q1 23	-$36M	-$36M
Q2 23	-$26M	-$26M
Q3 23	-$29M	-$29M
Q4 23	-$34M	-$34M
Q1 24	-$49M	-$49M
Q2 24	-$43M	-$43M
Q3 24	-$43M	-$43M
Q4 24	$269M	$269M
Q1 25	-$72M	-$72M
Q2 25	-$29M	-$30M
Q3 25	-$81M	-$83M
Q4 25	$117M	$115M

Capital Expenditures

Quarter	CapEx
Q1 22	$49.0K
Q2 22	$184.0K
Q3 22	$381.0K
Q4 22	$12.0K
Q1 23	$36.0K
Q2 23	$96.0K
Q3 23	$20.0K
Q4 23	$16.0K
Q1 24	$84.0K
Q2 24	$16.0K
Q3 24	$0
Q4 24	$372.0K
Q1 25	$292.0K
Q2 25	$1M
Q3 25	$3M
Q4 25	$2M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+6.1%
Q2 22	—	+5.0%
Q3 22	—	+8.7%
Q4 22	—	+6.4%
Q1 23	—	+11.5%
Q2 23	—	+13.2%
Q3 23	—	+16.1%
Q4 23	—	+33.0%
Q1 24	—	+48.9%
Q2 24	—	+41.0%
Q3 24	—	+41.0%
Q4 24	—	+63.2%
Q1 25	—	+44.7%
Q2 25	—	+55.9%
Q3 25	—	+68.2%
Q4 25	-67.8%	+35.7%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$7M	—
Q2 22	$7M	—
Q3 22	$6M	—
Q4 22	$7M	—
Q1 23	$7M	—
Q2 23	$7M	—
Q3 23	$7M	—
Q4 23	$7M	—
Q1 24	$9M	—
Q2 24	$8M	—
Q3 24	$8M	—
Q4 24	$9M	16.0%
Q1 25	$8M	55.6%
Q2 25	$7M	45.5%
Q3 25	$11M	52.8%
Q4 25	$11M	65.5%

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$21M	$12M	—
Q2 22	$24M	$11M	—
Q3 22	$25M	$12M	—
Q4 22	$23M	$12M	—
Q1 23	$25M	$11M	—
Q2 23	$28M	$12M	—
Q3 23	$29M	—	$13M
Q4 23	$33M	—	$14M
Q1 24	$36M	$18M	—
Q2 24	$40M	$17M	—
Q3 24	$42M	$18M	—
Q4 24	$52M	$24M	—
Q1 25	$56M	$23M	—
Q2 25	$63M	$25M	—
Q3 25	$68M	$33M	—
Q4 25	$64M	$39M	—

Revenue Segments

Quarter	Operating Segments
Q2 25	$15M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$34M	$446M	$480M
Q2 22	$39M	$411M	$450M
Q3 22	$91M	$337M	$428M
Q4 22	$52M	$386M	$438M
Q1 23	$27M	$379M	$406M
Q2 23	$49M	$428M	$477M
Q3 23	$29M	$424M	$453M
Q4 23	$37M	$387M	$424M
Q1 24	$42M	$486M	$527M
Q2 24	$45M	$446M	$492M
Q3 24	$49M	$406M	$455M
Q4 24	$224M	$503M	$727M
Q1 25	$51M	$607M	$658M
Q2 25	$82M	$549M	$631M
Q3 25	$95M	$454M	$550M
Q4 25	$149M	$518M	$667M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	67M	+0.1%	+0.6%
Q2 22	67M	+0.1%	+0.6%
Q3 22	67M	+0.3%	+0.8%
Q4 22	68M	+1.3%	+1.8%
Q1 23	68M	+0.9%	+2.7%
Q2 23	70M	+2.0%	+4.7%
Q3 23	77M	+10.7%	+15.5%
Q4 23	77M	+0.1%	+14.1%
Q1 24	84M	+8.5%	+22.7%
Q2 24	87M	+3.3%	+24.1%
Q3 24	87M	+0.4%	+12.6%
Q4 24	87M	+0.2%	+12.7%
Q1 25	87M	+0.3%	+4.2%
Q2 25	88M	+0.2%	+1.1%
Q3 25	88M	+0.1%	+0.8%
Q4 25	88M	+0.5%	+1.0%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	121
Q2 22	$0	121
Q3 22	$0	121
Q4 22	$0	133
Q1 23	$0	133
Q2 23	$0	133
Q3 23	$0	133
Q4 23	$0	142
Q1 24	$0	142
Q2 24	$0	142
Q3 24	$0	142
Q4 24	$280.6K	192
Q1 25	$73.5K	192
Q2 25	$79.6K	192
Q3 25	$108.1K	192
Q4 25	$66.7K	260

Revenue / Employee